TXG
NASDAQ · Life Sciences Tools & Services
10X Genomics Inc-Class A
$34.76
+2.63 (+8.17%)
Financial Highlights (FY 2026)
Revenue
788.37M
Net Income
-53,410,399
Gross Margin
69.1%
Profit Margin
-6.8%
Rev Growth
+7.6%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 69.1% | 69.1% | 53.0% | 53.0% |
| Operating Margin | -9.5% | -8.5% | 5.2% | 5.5% |
| Profit Margin | -6.8% | -6.4% | 3.8% | 3.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 788.37M | 732.89M | 3.76B | 3.57B |
| Gross Profit | 545.00M | 506.64M | 2.00B | 1.89B |
| Operating Income | -74,815,899 | -62,595,806 | 195.82M | 196.35M |
| Net Income | -53,410,399 | -44,686,584 | 142.18M | 130.84M |
| Gross Margin | 69.1% | 69.1% | 53.0% | 53.0% |
| Operating Margin | -9.5% | -8.5% | 5.2% | 5.5% |
| Profit Margin | -6.8% | -6.4% | 3.8% | 3.7% |
| Rev Growth | +7.6% | +7.6% | +0.2% | +15.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 371.66M | 344.77M |
| Total Equity | — | — | 1.19B | 1.40B |
| D/E Ratio | — | — | 0.31 | 0.25 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -30,400,018 | -26,847,649 | 232.37M | 259.66M |
| Free Cash Flow | — | — | 156.81M | 93.65M |